search
Back to results

DISTRESS Trial Functional Disorders - the DISTRESS Trial (DISTRESS)

Primary Purpose

Bodily Distress Syndrome, Functional Somatic Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders
Diagnostic as usual
Sponsored by
Regionshospitalet Silkeborg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Bodily Distress Syndrome focused on measuring Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome, Somatoform Disorders

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Study population: Participants were drawn from the population of the Central Denmark Region. To be considered for inclusion, patients had to be referred by their GP. Inclusion Criteria: Being referred to the clinic by their GP due to symptoms consistent with a possible diagnosis of moderate or severe FSD. Symptoms having been present for at least 6 months and no more than 3 years. Having undergone at least 2 diagnostic evaluations (e.g. imaging studies or specialist evaluations) at physical specialty clinics or hospitals in the past year. Age 18-60. Being of ethnic western cultural upbringing. Understands and speaks Danish fluently. Exclusion Criteria: Having another severe chronic disease which explains the reduced level of functioning. Having been previously referred to or evaluated for FSD at this or another clinic specializing in functional disorders. Previous diagnosis of FSD. Alcohol or other substance-dependency or -abuse. Emergent psychiatric illness or emergent elevated risk of harm to self or others requiring psychiatric evaluation for possible need of acute or sub-acute psychiatric hospitalization. Current or prior diagnosis of psychosis (ICD10 F2x diagnosis), bipolar affective disorder (ICD10 F31.x diagnosis) or depression with psychotic symptoms (ICD10 F32.3 or F33.3 diagnosis). Currently pregnant.

Sites / Locations

  • Regionshospitalet SilkeborgRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention arm

Control arm

Arm Description

Patients referred by their GP under suspicion of suffering from FSD are randomized to the intervention arm.

Patients referred by their GP under suspicion of suffering from FSD are randomized to "Diagnostic as usual" in the control arm.

Outcomes

Primary Outcome Measures

Healthcare services utilization (i.e. direct costs)
Comparison of healthcare services utilization (of secondary and tertiary sector care) by the intervention group, compared to the control group. Data shall be drawn from Danish national and regional healthcare service registers.
Cost-effectiveness analysis (CEA) (direct and indirect costs)
Cost-effectiveness analysis (CEA), comparing the intervention and the control group from both a healthcare (direct costs) and a societal perspective (indirect costs) combining data on incremental costs and incremental effects; adjusted for differences in mean utility score and mean costs at baseline (1 year prior to randomization).

Secondary Outcome Measures

Public expenses associated with occupational status and social benefits (i.e. indirect costs)
Comparison of expenses associated with occupational status and social benefits of the intervention group, compared to the control group. Data shall be drawn from the Danish Register-based Evaluation of Marginalisation (DREAM) database.
Effectiveness: Health-related quality of life (via the the Short Form 36 Total Score)
Difference between the intervention group and the control group in health-related quality of life, measured by the Total Score of the Short Form 36 (SF-36). The SF-36 is summarized in a score on a scale from 0-100 where 100 is the best possible health-related quality of life.
Effectiveness: Perceived physical health
Difference between the intervention group and the control group in perceived physical health, measured by an aggregate score of the 'physical functioning', 'bodily pain' and 'vitality' subscales of the Short Form-36. This aggregate score has a minimum of 15 and a maximum of 65 and a higher score indicates better physical health. This outcome encompasses physical domains which have been previously found to be affected in functional somatic disorders.
Effectiveness (via Patient-reported Clinical Global Improvement)
Patients evaluate their overall health as "much worse", " somewhat worse ", "about the same", "somewhat better" or "much better" compared to 1 year prior, at 3 and 12 months after randomization. Specifically, we shall compare the share of patients in the intervention group vs. the control group who evaluate their overall health as "somewhat better" or "much better".

Full Information

First Posted
August 7, 2023
Last Updated
August 29, 2023
Sponsor
Regionshospitalet Silkeborg
Collaborators
Aarhus University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06025617
Brief Title
DISTRESS Trial Functional Disorders - the DISTRESS Trial
Acronym
DISTRESS
Official Title
Comprehensive Evaluation of a New Diagnostic Clinic for Functional Disorders - the DISTRESS Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2019 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
September 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Regionshospitalet Silkeborg
Collaborators
Aarhus University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A Diagnostic Clinic for Functional Somatic Disorders (FSD) has been set up at the outpatient diagnostic center at Regionshospitalet Silkeborg. The objective of the clinic is to support General Practitioners (GPs) by offering early stage diagnostic evaluation of whether a patient has an FSD or the symptoms were caused by another physical illness or mental disorder. As a novelty in this project, Internal Medicine consultants examine the patients for FSD, after having received training in diagnosing FSD by FSD experts. By performing diagnostic evaluation for physical diseases and FSD simultaneously, the investigators believe that the new clinic shall be able to accelerate the establishment of a final diagnosis for these patients who would otherwise likely undergo a protracted diagnostic course involving sequential evaluations at various specialty clinics. The DISTRESS trial is a pragmatic randomized clinical trial which aims to evaluate the Diagnostic Clinic for FSD in terms of clinical cost-effectiveness outcomes.
Detailed Description
Functional Somatic Disorders (FSD) are conditions where patients present with characteristic patterns of physical symptoms, accompanied by impairment or disability. FSD is a clinical diagnosis for which no clinical or paraclinical tests at present have been found useable for establishing the diagnosis. The disorders range from mild and transient to severe, chronic and disabling, and are common in all medical settings, both in primary and secondary care. FSD is costly for society due to high health care use, and the reduction of patients' labor market participation. Arguably, insufficient diagnostic availability is part of the reason some patients develop more severe, chronic and disabling FSD. The Diagnostic Clinic for FSD was set up at Regionshospitalet to alleviate this diagnostic need in the secondary care setting. The DISTRESS trial is a pragmatic randomized clinical trial. After referral by their GP, patients are randomized 1:1 into two study arms: Intervention and Control. The referring GP must specify which diagnostic evaluations he/she requests both in the intervention and in the control group. Intervention arm: Patients in this arm shall be examined by an internal medicine specialist trained in FSD diagnostic evaluation at The Diagnostic Clinic for FSD. After parallel evaluation for FSD and other physical conditions, patients are given their diagnosis, along with patient education in what FSD is, as well as a letter to their GP regarding recommended management and treatment options. Control arm: The comparison group in the randomized clinical trial will receive diagnostic as usual at the Diagnostic center or elsewhere in the secondary sector in The Central Denmark Region. In this clinical trial, the investigators aim to evaluate the effectiveness in terms of health-related utility improvement for the patients as well as the healthcare and societal costs and cost-effectiveness of the clinic, compared to diagnostic as usual.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bodily Distress Syndrome, Functional Somatic Disorder
Keywords
Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome, Somatoform Disorders

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Masking Description
Outcome data is blinded to the investigator during data analysis as to intervention vs. comparison arm assignment.
Allocation
Randomized
Enrollment
352 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention arm
Arm Type
Experimental
Arm Description
Patients referred by their GP under suspicion of suffering from FSD are randomized to the intervention arm.
Arm Title
Control arm
Arm Type
Active Comparator
Arm Description
Patients referred by their GP under suspicion of suffering from FSD are randomized to "Diagnostic as usual" in the control arm.
Intervention Type
Other
Intervention Name(s)
Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders
Intervention Description
The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
Intervention Type
Other
Intervention Name(s)
Diagnostic as usual
Intervention Description
"Diagnostic as usual" consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP.
Primary Outcome Measure Information:
Title
Healthcare services utilization (i.e. direct costs)
Description
Comparison of healthcare services utilization (of secondary and tertiary sector care) by the intervention group, compared to the control group. Data shall be drawn from Danish national and regional healthcare service registers.
Time Frame
12 months prior to randomization and 12 months' follow-up
Title
Cost-effectiveness analysis (CEA) (direct and indirect costs)
Description
Cost-effectiveness analysis (CEA), comparing the intervention and the control group from both a healthcare (direct costs) and a societal perspective (indirect costs) combining data on incremental costs and incremental effects; adjusted for differences in mean utility score and mean costs at baseline (1 year prior to randomization).
Time Frame
12 months prior to randomization and 12 months' follow-up
Secondary Outcome Measure Information:
Title
Public expenses associated with occupational status and social benefits (i.e. indirect costs)
Description
Comparison of expenses associated with occupational status and social benefits of the intervention group, compared to the control group. Data shall be drawn from the Danish Register-based Evaluation of Marginalisation (DREAM) database.
Time Frame
12 months prior to randomization and 12 months' follow-up
Title
Effectiveness: Health-related quality of life (via the the Short Form 36 Total Score)
Description
Difference between the intervention group and the control group in health-related quality of life, measured by the Total Score of the Short Form 36 (SF-36). The SF-36 is summarized in a score on a scale from 0-100 where 100 is the best possible health-related quality of life.
Time Frame
Baseline, 3- and 12-months' follow-up
Title
Effectiveness: Perceived physical health
Description
Difference between the intervention group and the control group in perceived physical health, measured by an aggregate score of the 'physical functioning', 'bodily pain' and 'vitality' subscales of the Short Form-36. This aggregate score has a minimum of 15 and a maximum of 65 and a higher score indicates better physical health. This outcome encompasses physical domains which have been previously found to be affected in functional somatic disorders.
Time Frame
Baseline, 3- and 12-months' follow-up
Title
Effectiveness (via Patient-reported Clinical Global Improvement)
Description
Patients evaluate their overall health as "much worse", " somewhat worse ", "about the same", "somewhat better" or "much better" compared to 1 year prior, at 3 and 12 months after randomization. Specifically, we shall compare the share of patients in the intervention group vs. the control group who evaluate their overall health as "somewhat better" or "much better".
Time Frame
At 3- and 12-months' follow-up
Other Pre-specified Outcome Measures:
Title
Symptom level comparison
Description
Comparison of the intervention group and the control group regarding the number and severity of symptoms via the Bodily Distress Syndrome 25 (BDS-25) symptom checklist. This checklist asks 'have you been bothered by', followed by a list of 25 symptoms comprising the four symptom clusters of Bodily Distress Syndrome (BDS). The checklist measures symptoms on a 5-point rating scale from 0 ('not at all bothersome') to 4 ('a lot bothersome'). The sum score is calculated by adding the single item scores from the 25 items (ranging from 0 to 100, where a higher score implies greater bother from symptoms).
Time Frame
At 3- and 12 months follow-up
Title
Health anxiety
Description
Comparison of the intervention group and the control group regarding health anxiety using Whiteley-6-R index. The Whiteley indices measure health anxiety. The Whiteley-6-R, which excludes two items on somatic symptoms while adding one item on obsessive rumination has been found to have better psychometric properties. The Whiteley-6-R has a total score range of 0-24, where a higher score indicates a higher level of health anxiety.
Time Frame
At 3- and 12 months follow-up
Title
Overall physical health
Description
Overall health is assessed with a single item from the 36-item Short-Form Health Survey (SF-36), estimating self-perceived health on a 5-point rating scale from 'excellent' to 'poor'. Higher score on this item indicates poorer health.
Time Frame
At 3- and 12 months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Study population: Participants were drawn from the population of the Central Denmark Region. To be considered for inclusion, patients had to be referred by their GP. Inclusion Criteria: Being referred to the clinic by their GP due to symptoms consistent with a possible diagnosis of moderate or severe FSD. Symptoms having been present for at least 6 months and no more than 3 years. Having undergone at least 2 diagnostic evaluations (e.g. imaging studies or specialist evaluations) at physical specialty clinics or hospitals in the past year. Age 18-60. Being of ethnic western cultural upbringing. Understands and speaks Danish fluently. Exclusion Criteria: Having another severe chronic disease which explains the reduced level of functioning. Having been previously referred to or evaluated for FSD at this or another clinic specializing in functional disorders. Previous diagnosis of FSD. Alcohol or other substance-dependency or -abuse. Emergent psychiatric illness or emergent elevated risk of harm to self or others requiring psychiatric evaluation for possible need of acute or sub-acute psychiatric hospitalization. Current or prior diagnosis of psychosis (ICD10 F2x diagnosis), bipolar affective disorder (ICD10 F31.x diagnosis) or depression with psychotic symptoms (ICD10 F32.3 or F33.3 diagnosis). Currently pregnant.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael M Madsen, MD MPH MSc
Phone
+4578415000
Email
michms@rm.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael M Madsen, MD MPH MSc
Organizational Affiliation
Regionshospitalet Silkeborg
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lise K Gormsen, MD PhD
Organizational Affiliation
Funktionelle Lidelser, Aarhus Universitetshospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christian Trolle, MD PhD
Organizational Affiliation
Regionshospitalet Silkeborg
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Per Fink, MD Dr. Med PhD
Organizational Affiliation
Funktionelle Lidelser, Aarhus Universitetshospital
Official's Role
Study Director
Facility Information:
Facility Name
Regionshospitalet Silkeborg
City
Silkeborg
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Sofie B Glenting, Cand.cur
Phone
+78417865
Email
ANNJE9@rm.dk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

DISTRESS Trial Functional Disorders - the DISTRESS Trial

We'll reach out to this number within 24 hrs